Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
3R01CA037082-02S1
Application #
3174765
Study Section
Medicinal Chemistry Study Section (MCHA)
Project Start
1983-07-01
Project End
1986-04-30
Budget Start
1984-06-01
Budget End
1986-04-30
Support Year
2
Fiscal Year
1986
Total Cost
Indirect Cost

  Institution

Name
University of Tennessee Health Science Center
Department
Type
Schools of Medicine
DUNS #
941884009
City
Memphis
State
TN
Country
United States
Zip Code
38163

  Publications

Chuang, L F; Kung, H F; Israel, M et al. (1992) Activation of human leukemia protein kinase C by tumor promoters and its inhibition by N-trifluoroacetyladriamycin-14-valerate (AD 32). Biochem Pharmacol 43:865-72
Lothstein, L; Sweatman, T W; Dockter, M E et al. (1992) Resistance to N-benzyladriamycin-14-valerate in mouse J774.2 cells: P-glycoprotein expression without reduced N-benzyladriamycin-14-valerate accumulation. Cancer Res 52:3409-17
Lothstein, L; Wright, H M; Sweatman, T W et al. (1992) N-benzyladriamycin-14-valerate and drug resistance: correlation of anthracycline structural modification with intracellular accumulation and distribution in multidrug resistant cells. Oncol Res 4:341-7
Sweatman, T W; Seshadri, R; Israel, M (1990) Metabolism and elimination of rhodamine 123 in the rat. Cancer Chemother Pharmacol 27:205-10
Bodley, A; Liu, L F; Israel, M et al. (1989) DNA topoisomerase II-mediated interaction of doxorubicin and daunorubicin congeners with DNA. Cancer Res 49:5969-78
Israel, M; Sweatman, T W; Seshadri, R et al. (1989) Comparative uptake and retention of adriamycin and N-benzyladriamycin-14-valerate in human CEM leukemic lymphocyte cell cultures. Cancer Chemother Pharmacol 25:177-83
Zhao, F K; Chuang, L F; Israel, M et al. (1989) Adriamycin interacts with diacylglycerol to inhibit human leukemia protein kinase C. Anticancer Res 9:225-9
Zhao, F K; Chuang, L F; Israel, M et al. (1989) Cremophor EL, a widely used parenteral vehicle, is a potent inhibitor of protein kinase C. Biochem Biophys Res Commun 159:1359-67
Lameh, J; Chuang, R Y; Israel, M et al. (1989) Nucleoside uptake and membrane fluidity studies on N-trifluoroacetyladriamycin-14-O-hemiadipate-treated human leukemia and lymphoma cells. Cancer Res 49:2905-8
Ganapathi, R; Grabowski, D; Sweatman, T W et al. (1989) N-benzyladriamycin-14-valerate versus progressively doxorubicin-resistant murine tumours: cellular pharmacology and characterisation of cross-resistance in vitro and in vivo. Br J Cancer 60:819-26

Showing the most recent 10 out of 22 publications